Navigation Links
Indication of considerable added benefit of vemurafenib in advanced melanoma
Date:1/8/2013

The drug vemurafenib (trade name Zelboraf) has been approved since February 2012 for the treatment of advanced melanoma (cancer of the skin cells that produce the dark pigment, melanin). It can be an option for adults whose melanoma cannot be removed by surgery or has formed secondaries (metastases) and in whose cancer a change (mutation) has occurred in a certain gene (BRAF-V600). The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, major advantages in terms of overall survival are accompanied by major potential harm in the form of side effects. Overall, there is an indication that vemurafenib offers considerable added benefit.

Vemurafenib in comparison with dacarbazine

The Federal Joint Committee (G-BA) has specified the drug dacarbazine as the appropriate comparator therapy. One study that compared vemurafenib directly with dacarbazine was available for the benefit assessment. This is a randomized and open-label study, i.e. patients were randomly assigned to one of the two treatment groups and both they and their doctors knew which of the two drugs was used in each case.

Longer survival means major added benefit

IQWiG always assesses a drug with a view to patient-relevant outcomes such as survival (mortality), symptoms and complications (morbidity) as well as quality of life. The study provides an indication that vemurafenib can prolong life. While half of the patients who received dacarbazine died after less than 10 months, in the vemurafenib group this was the case only after more than 13 months. The differing course of the two survival curves provides an indication of a major added benefit of vemurafenib.

Pain was the only outcome recorded in the study in relation to morbidity. There were, however, no statistically significant diff
'/>"/>

Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
0049-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Antibody-coated stents: Indication of disadvantages
2. Abiraterone: Indication of considerable added benefit in certain patients
3. Considerable added benefit of ipilimumab in advanced melanoma
4. Marketing Xocolate International Corporation (MXI-Corp) Introduces Xe Healthy Energy Drink, A Rich And Delicious Antioxidant Beverage, Now Added to Xoçai™ Product Line
5. Capsiplex Plus Reviews for Improved Weight Loss Supplement Added to BestAppetiteSuppressantPills.com
6. UV-Aid Cold and Flu Prevention Added to List of Biomimicry Strategies on AskNature.Org
7. Healthy Chocolate Omega Squares, a Decedent Dark Chocolate Added to Marketing Xocolate International Corporation (MXI Corp) Product Lines
8. Rilpivirine for HIV: Added benefit for single agent proven
9. US Drug Watchdog Has Added Wright, Stryker, Biomet, and Zimmer To Their Initiative For All Metal Hip Implant Failures Victims & Offers Them The Names Of The Best Lawyers
10. CFO 911 Solutions' Charles K. Dargan II, CEO, and Reid Dabney, Managing Director Have Been Added to the Financial Entrepreneur Platform ("FEP") of Merriman Capital, Inc., a Wholly Owned Subsidiary of Merriman Holdings, Inc. (OTCQX: MERR)
11. Vandetanib in thyroid cancer: No proof of added benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 VHA Central ... for excellence in clinical care, honoring nine facilities for ... patient experience. , “At Novant Health, providing quality, affordable ... priority” said Tom Zweng, MD, executive vice president and ... to provide a remarkable experience for each and every ...
(Date:8/29/2014)... For the fifth year in a ... be observing September 26th as Mesothelioma Awareness Day, by ... York. , Members of the community who wish ... Foundation will be providing t-shirts and signs to participating ... members have received attention from Al Roker ...
(Date:8/29/2014)... 2014 Parker Waichman LLP, a national ... the rights of victims who have been injured by ... announced new regulations for all hydrocodone combination products. According ... report dated August 21, 2014, the DEA will be ... federal law. , The long-awaited announcement comes after ...
(Date:8/29/2014)... Empty Nest Syndrome on Dr. Carol ... , Mothers and fathers, who dedicated the last ... laughing and sweating through parenting, launch their college ... Relief and parenting pride intermix with loss, depression ... Carol Francis as a Clinical Psychologist has helped ...
(Date:8/29/2014)... 2014 Bedros Keuilian recently stepped outside his ... expert on the new Spike TV reality show, Gym ... searched Google for an expert in boot camp marketing and ... Now Keuilian has just released a webinar explaining how fitness ... status as experts and increase their client base. , In ...
Breaking Medicine News(10 mins):Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 2Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 3
... 1 Arete Therapeutics Inc. today,announced the initiation ... lead compound,AR9281, for the treatment of hypertension. AR9281 ... (s-EH), a novel target,for the treatment of hypertension. ... volunteers and will evaluate the safety, tolerability,pharmacokinetics and ...
... 1 Amira Pharmaceuticals, Inc. announced,completion of the ... discovered oral drug candidate for the treatment of ... announced the start,of a Phase 1 trial for ... the,same inflammatory response. AM103 and AM803 are ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... BASINGSTOKE, England and PHILADELPHIA, November 1, Shire plc (LSE: SHP, ... for the third,quarter 2007. Q3 2007 Financial Highlights ... Total revenues up 35% to $608.7 million; - Net ... and - 2007 revenue growth now expected to be ...
... Innovative Approach to Preventing Kidney Damage during ... ... (Amex: PLC ), a,company focused on innovative cardiac and vascular ... Renal Week, the American Society of Nephrology,s 40th,Annual Meeting and Scientific ...
... of the cells might lead to treatments, researchers say , THURSDAY, ... found stem cells within the intervertebral discs of the human spine. ... stem cells to help repair degenerating discs in order to treat ... the Nov. 1 issue of the journal Spine . , ...
Cached Medicine News:Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data ... new website design . The main website, along ... showcases the company,s new services and content relevant to ... a new streamlined design, viewers can now better understand ... health care practices and create a more visible platform ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 ... DMPI) ("DelMar" "the Company") today announced the filing of ... recently changed its fiscal year end to June 30th ... common stock on a national securities exchange in the ... filed with the United States Securities Exchange Commission can ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2PMDS Announces New Website 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
... speed and accuracy allow clinical staff ... timely manner - something everyone in ... In fact, the Rapidlab 1200 delivers ... one minute. Its maintenance-free, cartridge-based system ...
... Fibertom is a 60 watt diode continuous wave ... of Diode Power Bar technology and 940 nm ... laser treatment for varicose veins and a variety ... includes unique safety features including the LPS, Light ...
... 28 Hue test studies the characteristic ... Farnsworth D15, however this 28 hue ... of sensitivity. Case comes with a ... readable. Kit includes laminated scoring template ...
... disc test for detecting and grading ... minutes for quantitative estimation of saturation ... sensitive to and specific for differences ... Combined with Ishiharas pseudo-isochromatic plates, discriminates ...
Medicine Products: